{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T12:20:32Z","timestamp":1784290832818,"version":"3.55.0"},"reference-count":10,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","award":["CSDG-19-001-01"],"award-info":[{"award-number":["CSDG-19-001-01"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.eururo.2021.10.009","type":"journal-article","created":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T08:45:55Z","timestamp":1635756355000},"page":"138-142","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["A Molecular Inquiry into the Role of Antibody-Drug Conjugates in Bacillus Calmette-Gu\u00e9rin-exposed Non\u2013muscle-invasive Bladder Cancer"],"prefix":"10.1016","volume":"81","author":[{"given":"Woonyoung","family":"Choi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kara","family":"Lombardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Epstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingxiao","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Gabrielson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noah M.","family":"Hahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Hoffman-Censits","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"McConkey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trinity J.","family":"Bivalacqua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andres","family":"Matoso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Kates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2021.10.009_b0005","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.eururo.2017.05.032","article-title":"Next-generation sequencing of nonmuscle invasive bladder cancer reveals potential biomarkers and rational therapeutic targets","volume":"72","author":"Pietzak","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2021.10.009_b0010","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.eururo.2020.06.048","article-title":"Identification of differential tumor subtypes of T1 bladder cancer","volume":"78","author":"Robertson","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2021.10.009_b0015","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.eururo.2018.09.002","article-title":"Genomic differences between \u201cprimary\u201d and \u201csecondary\u201d muscle-invasive bladder cancer as a basis for disparate outcomes to cisplatin-based neoadjuvant chemotherapy","volume":"75","author":"Pietzak","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2021.10.009_b0020","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S1470-2045(21)00147-9","article-title":"Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study","volume":"22","author":"Balar","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2021.10.009_b0025","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1200\/JCO.19.01140","article-title":"Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1\/programmed death ligand 1 therapy","volume":"37","author":"Rosenberg","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2021.10.009_b0030","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1200\/JCO.20.03489","article-title":"TROPHY-U-01: a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors","volume":"39","author":"Tagawa","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2021.10.009_b0035","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1038\/s41467-021-22465-w","article-title":"An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer","volume":"12","author":"Lindskrog","year":"2021","journal-title":"Nat Commun"},{"issue":"18","key":"10.1016\/j.eururo.2021.10.009_b0040","doi-asserted-by":"crossref","first-page":"5123","DOI":"10.1158\/1078-0432.CCR-20-4175","article-title":"Heterogeneity in NECTIN-4 Expression Across Molecular Subtypes of Urothelial Cancer Mediates Sensitivity to Enfortumab Vedotin","volume":"27","author":"Chu","year":"2021","journal-title":"Clin Cancer"},{"issue":"6 Suppl","key":"10.1016\/j.eururo.2021.10.009_b0045","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1200\/JCO.2020.38.6_suppl.441","article-title":"Study EV-103: preliminary durability results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma","volume":"38","author":"Rosenberg","year":"2020","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.eururo.2021.10.009_b0050","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/s41591-021-01317-6","article-title":"An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer","volume":"27","author":"Powles","year":"2021","journal-title":"Nat Med"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283821020777?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283821020777?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T13:09:49Z","timestamp":1759583389000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283821020777"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":10,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S0302283821020777"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2021.10.009","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Molecular Inquiry into the Role of Antibody-Drug Conjugates in Bacillus Calmette-Gu\u00e9rin-exposed Non\u2013muscle-invasive Bladder Cancer","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2021.10.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}